The DurAVR transcatheter heart valve, developed by Minnesota-based Anteris Technologies, was designed to move and perform like a healthy, pre-disease native aortic valve.

The device, designed with improved filtration and stability in mind, is now being investigated as part of a new pilot study. 

The device, now on display at TVT 2023 in Phoenix, is scheduled to begin hitting the market in the months ahead. 

A new retrospective study from the Mayo Clinic focused on patients with no other need for anticoagulation.

In-hospital mortality and other key outcomes have improved in recent years, but treating these older patients is still associated with certain challenges. 

A new-look TAVR valve was tested on patients for the first time, leading researchers to say its use appears to be "feasible and safe." More research, of course, is still required. 

Catch up on key late-breaking research from Abbott, Edwards Lifesciences and Philips presented at the four-day meeting in Paris. 

An Ohio doctor allegedly performed multiple procedures without the proper credentials. A vascular surgeon is now out of work for sharing the story with a local media outlet.